Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03888222 · ClinicalTrials.gov registry record · Phase 2
Impact of Bosutinib on Safety, Tolerability, Biomarkers and Clinical Outcomes in Dementia With Lewy Bodies
A Phase 2 study, sponsored by Georgetown University.
- Completed
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
NCT03888222 is a Phase 2 study that has completed, run by Georgetown University. The registered enrollment target is 26 participants.
The verdict
NCT03888222, a Phase 2 study, has completed, sponsored by Georgetown University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
Study Summary
This study evaluates the effect of Bosutinib (Bosulif,Pfizer®) in the treatment of patients with Dementia with Lewy Bodies. Half participants will receive 100 mg of Bosutinib , while the other half will receive placebo.
Interventions
- DRUG Placebo Oral Tablet
- DRUG Bosutinib Oral Tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2019-04-23 |
| Est. Completion | 2021-08-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03888222
The ClinicalTrials.gov registry entry for NCT03888222 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Georgetown University, which has 227 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo Oral Tablet is the first listed.
NCT03888222 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03888222 about?
NCT03888222 is a clinical study titled "Impact of Bosutinib on Safety, Tolerability, Biomarkers and Clinical Outcomes in Dementia With Lewy Bodies". This study evaluates the effect of Bosutinib (Bosulif,Pfizer®) in the treatment of patients with Dementia with Lewy Bodies. Half participants will receive 100 mg of Bosutinib , while the other half will receive placebo.
What is the current status of trial NCT03888222?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2019-04-23. Estimated completion is 2021-08-27.
What interventions are being tested in trial NCT03888222?
The interventions under investigation include: Placebo Oral Tablet (DRUG), Bosutinib Oral Tablet (DRUG).
Who is sponsoring clinical trial NCT03888222?
This trial is sponsored by Georgetown University, which has 227 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.